References

Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11

10.1016/s2213-2600(14)70101-8 · 2014 · External reference

Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS(R) trials

10.1186/s12931-020-1298-1 · 2020 · External reference

Impact of idiopathic pulmonary fibrosis on longitudinal health-care utilization in a community-based cohort of patients

10.1016/j.chest.2020.07.035 · 2021 · External reference

Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline

10.1164/rccm.202202-0399st · 2022 · External reference

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis

10.1056/nejmoa1402582 · 2014 · External reference

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

10.1056/nejmoa1402584 · 2014 · External reference

Nerandomilast in patients with idiopathic pulmonary fibrosis

10.1056/nejmoa2414108 · 2025 · External reference

Clinical course and prediction of survival in idiopathic pulmonary fibrosis

10.1164/rccm.201006-0894ci · 2011 · External reference

Forced vital capacity trajectories in patients with idiopathic pulmonary fibrosis: a secondary analysis of a multicentre, prospective, observational cohort

10.1016/s2589-7500(22)00173-x · 2022 · External reference

Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern

10.1371/journal.pone.0000482 · 2007 · External reference

MUC5B promoter polymorphism and interstitial lung abnormalities

10.1056/nejmoa1216076 · 2013 · External reference

Early interstitial lung disease in familial pulmonary fibrosis

10.1164/rccm.200702-254oc · 2007 · External reference

Development and progression of radiologic abnormalities in individuals at risk for familial interstitial lung disease

10.1164/rccm.201909-1834oc · 2020 · External reference

Interstitial lung abnormalities detected incidentally on CT: a position paper from the Fleischner Society

10.1016/s2213-2600(20)30168-5 · 2020 · External reference

Approach to the evaluation and management of interstitial lung abnormalities: an official American Thoracic Society clinical statement

10.1164/rccm.202505-1054st · 2025 · External reference

Extensive phenotyping of individuals at risk for familial interstitial pneumonia reveals clues to the pathogenesis of interstitial lung disease

10.1164/rccm.201406-1162oc · 2015 · External reference

Development and progression of interstitial lung abnormalities in the Framingham Heart Study

10.1164/rccm.201512-2523oc · 2016 · External reference

Association between interstitial lung abnormalities and all-cause mortality

10.1001/jama.2016.0518 · 2016 · External reference

High-attenuation areas on chest computed tomography and clinical respiratory outcomes in community-dwelling adults

10.1164/rccm.201703-0555oc · 2017 · External reference

Progressive early interstitial lung abnormalities in persons at risk for familial pulmonary fibrosis: a prospective cohort study

10.1164/rccm.202403-0524oc · 2024 · External reference

A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer’s disease

10.1002/sim.7811 · 2018 · External reference

Clinical and biomarker changes in dominantly inherited Alzheimer’s disease

10.1056/nejmoa1202753 · 2012 · External reference

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

10.1016/s0140-6736(11)60405-4 · 2011 · External reference

Disease progression modeling identifies a conserved pattern of lung function decline in familial pulmonary fibrosis

10.1164/ajrccm.2025.211.abstracts.a3236 · 2025 · External reference

The genetic landscape of familial pulmonary fibrosis

10.1164/rccm.202204-0781oc · 2023 · External reference

A race-neutral approach to the interpretation of lung function measurements

10.1164/rccm.202205-0963oc · 2023 · External reference

Official ERS technical standard: Global Lung Function Initiative reference values for static lung volumes in individuals of European ancestry

10.1183/13993003.00289-2020 · 2021 · External reference

Official ERS technical standards: Global Lung Function Initiative reference values for the carbon monoxide transfer factor for Caucasians

10.1183/13993003.00010-2017 · 2017 · External reference

Official ERS technical standards: Global Lung Function Initiative reference values for the carbon monoxide transfer factor for Caucasians

10.1183/13993003.00010-2017 · 2017 · External reference

Bayesian model of disease progression in GNE myopathy

10.1002/sim.8050 · 2019 · External reference

Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis

10.1164/rccm.200211-1311oc · 2003 · External reference

Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test

10.1164/rccm.200604-488oc · 2006 · External reference

Idiopathic pulmonary fibrosis: gender-age-physiology index stage for predicting future lung function decline

10.1378/chest.15-0530 · 2016 · External reference

Changes in lung function and mortality risk in patients with idiopathic pulmonary fibrosis

10.1016/j.chest.2025.02.018 · 2025 · External reference

Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report

10.1164/rccm.201604-0801ci · 2016 · External reference

Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosis

10.1136/thoraxjnl-2021-218577 · 2022 · External reference

A polygenic risk score for idiopathic pulmonary fibrosis and interstitial lung abnormalities

10.1164/rccm.202212-2257oc · 2023 · External reference

Smoking-related idiopathic interstitial pneumonia

10.1183/09031936.00166813 · 2014 · External reference

Mortality surrogates in combined pulmonary fibrosis and emphysema

10.1183/13993003.00127-2023 · 2024 · External reference

Approach to clinical trials for the prevention of pulmonary fibrosis

10.1513/annalsats.202303-188ps · 2023 · External reference

Pulmonary fibrosis stakeholder summit: a joint NHLBI, Three Lakes Foundation, and Pulmonary Fibrosis Foundation workshop report

10.1164/rccm.202307-1154ws · 2024 · External reference

Meaningful endpoints for idiopathic pulmonary fibrosis (IPF) clinical trials: emphasis on ‘feels, functions, survives.’ Report of a collaborative discussion in a symposium with direct engagement from representatives of patients, investigators, the National Institutes of Health, a patient advocacy organization, and a regulatory agency

10.1164/rccm.202312-2213so · 2024 · External reference

Predicting outcomes in idiopathic pulmonary fibrosis using automated computed tomographic analysis

10.1164/rccm.201711-2174oc · 2018 · External reference

Deep learning-based segmentation of computed tomography scans predicts disease progression and mortality in idiopathic pulmonary fibrosis

10.1164/rccm.202311-2185oc · 2024 · External reference

Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis

10.1016/s2213-2600(21)00503-8 · 2022 · External reference

Intersession variability in single-breath diffusing capacity of carbon monoxide

10.1016/j.chest.2025.09.006 · 2026 · External reference

Galectin-3 is associated with restrictive lung disease and interstitial lung abnormalities

10.1164/rccm.201509-1753oc · 2016 · External reference

Serum matrix metalloproteinase-7, respiratory symptoms, and mortality in community-dwelling adults. MESA (Multi-Ethnic Study of Atherosclerosis)

10.1164/rccm.201701-0254oc · 2017 · External reference

Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span

10.1084/jem.20162152 · 2017 · External reference

Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis

10.1126/sciadv.aba1972 · 2020 · External reference